Inventiva (NASDAQ:IVA) Trading Up 11.1% – Should You Buy?

Shares of Inventiva S.A. Sponsored ADR (NASDAQ:IVA) were up 11.1% during trading on Friday . The stock traded as high as $4.32 and last traded at $4.31. Approximately 73,880 shares were traded during mid-day trading, a decline of 5% from the average daily volume of 77,570 shares. The stock had previously closed at $3.88.

Analyst Ratings Changes

Several brokerages have issued reports on IVA. Weiss Ratings reissued a “sell (d-)” rating on shares of Inventiva in a research report on Wednesday, October 8th. Canaccord Genuity Group reiterated a “buy” rating and set a $20.00 target price on shares of Inventiva in a research note on Tuesday, September 30th. Wall Street Zen raised Inventiva to a “hold” rating in a report on Saturday, October 18th. Guggenheim reduced their price objective on Inventiva from $13.00 to $11.00 and set a “buy” rating for the company in a research note on Tuesday. Finally, HC Wainwright lifted their target price on Inventiva from $20.00 to $24.00 and gave the company a “buy” rating in a research note on Thursday, October 9th. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $17.29.

Inventiva Stock Up 10.7%

The firm has a fifty day moving average price of $5.06 and a 200 day moving average price of $4.20.

Hedge Funds Weigh In On Inventiva

A number of large investors have recently made changes to their positions in the stock. Wealth Enhancement Advisory Services LLC boosted its holdings in Inventiva by 54.5% during the second quarter. Wealth Enhancement Advisory Services LLC now owns 16,558 shares of the company’s stock worth $50,000 after buying an additional 5,843 shares in the last quarter. Creative Planning acquired a new stake in shares of Inventiva during the 2nd quarter valued at approximately $32,000. NewEdge Advisors LLC purchased a new stake in shares of Inventiva during the 3rd quarter worth approximately $116,000. Finally, Millennium Management LLC acquired a new stake in shares of Inventiva in the 3rd quarter worth approximately $649,000. Hedge funds and other institutional investors own 19.06% of the company’s stock.

About Inventiva

Inventiva SA, a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI.